SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-015500
Filing Date
2022-08-08
Accepted
2022-08-08 16:02:16
Documents
71
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q apls-20220630.htm   iXBRL 10-Q 2803888
2 EX-31.1 apls-ex31_1.htm EX-31.1 21151
3 EX-31.2 apls-ex31_2.htm EX-31.2 20347
4 EX-32.1 apls-ex32_1.htm EX-32.1 11579
5 EX-32.2 apls-ex32_2.htm EX-32.2 11732
  Complete submission text file 0000950170-22-015500.txt   9004472

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT apls-20220630.xsd EX-101.SCH 63438
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT apls-20220630_cal.xml EX-101.CAL 52245
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT apls-20220630_def.xml EX-101.DEF 194654
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT apls-20220630_pre.xml EX-101.PRE 324827
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT apls-20220630_lab.xml EX-101.LAB 453978
65 EXTRACTED XBRL INSTANCE DOCUMENT apls-20220630_htm.xml XML 1509995
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 221144241
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences